Antiphospholipid syndrome (APS) is a prothrombotic condition that can affect both the venous circulation and the arterial system. The deep veins of the lower extremities and cerebral blood flow are the most common sites of venous and arterial thrombosis, respectively. Skin ulceration and gangrene may be associated with an active vasculitis in patients with APS. These kinds of ulcers are considered intractable because healing is difficult to achieve. Using steroids as immunesuppressant therapy is still a basic part of managing APS and vasculitis. Nevertheless, in the presence of steroid-induced diabetes mellitus, the priority is to achieve faster wound healing, because of the potential complications that can develop due to metabolic dysfunction and augmented vulnerability to infection. Until recently, there were few reports demonstrating the benefits of the use of adjuvant phosphodiesterase-5 inhibitors like sildenafil citrate in different clinical entities with courses like Raynaud's phenomenon, scleroderma, and resistance to vasodilator therapy. We present the first report demonstrating the additional benefit of sildenafil citrate for the integration of grafts in a patient with steroid-induced diabetes and APS who had ulcers due to vasculitis resistant to the usual vasodilator therapy.
Introduction
Antiphospholipid syndrome (APS) is a prothrombotic condition that can affect both the venous circulation and arterial system [1] [2] . The deep veins of the lower extremities and cerebral blood flow are the most common sites of venous and arterial thrombosis, respectively [2] .
The presence of antiphospholipid antibodies (APAs) is recognized as one of the pathogenic mechanisms of action in APS, andis highly variable. When attached to membrane phospholipids, APAs can inhibit reactions in the coagulation cascade that are catalyzed by these membrane phospholipids, promoting proadhesive, proinflammatory, and prothrombotic effects on endothelial cells [3] .
The major autoantigen for APAs is ß-2-glycoprotein-1, which is a plasma apolipoprotein that mediates the binding of APAs to target plasma apolipoproteins on cells (e.g., platelets, monocytes, endothelial cells, and trophoblasts) [3] - [5] . Intensive research on the pathogenic mechanism during the past two decades led to various therapeutic strategies being proposed based on targeted therapies for APS [6] . However, the only validated treatment for APS is lifelong anticoagulation [7] . Antithrombotic drugs are currently used to prevent thromboembolic events in patients with APS [8] , but there is undoubtedly a need to develop adjuvant therapies for this autoimmune disease when it is associated with the presence of vasculitis.
On the other hand, steroids continue to be used as an adjuvant therapy with most of these drug combinations, and are administered in pulses despite the known complications associated with their use. Steroid use is not limited to hematological disorders, but is also useful as an immunosuppressant in other disease conditions, especially autoimmune diseases. Adverse effects associated with the use of steroids include gastritis, glaucoma, hypertension, impaired glucose tolerance, and diabetes mellitus. The latter is a clinical condition that can occur as a result of impaired insulin secretion or action, or the destruction of pancreatic beta cells [9] .
Therefore, we present the case of a patient with steroid-induced diabetes mellitus and APS complicated by vasculitis ulcers in which the adjuvant therapeutic effect of sildenafil citrate, an inhibitor of phosphodiesterase 5 (PDE-5), demonstrated additional benefits in the graft integration process.
Case Report
A 55-year-old male had a history of moderate smoking (10 cigarettes per day for 25 years), which was suspended because of his current condition. Starting in 1995 with the presence of severe pain in the popliteal space and enlargement of his left leg, an acute popliteal vein thrombus was identified by Doppler ultrasound. We investigated his risk factors for deep vein thrombosis (DVT) through laboratory tests, with the following results: negative anti-nuclear antibodies, anti-cardiolipin Ig Gantibodies (131.0 U.GPL/ml), anti-cardiolipin Ig Mantibodies (35.0 U•MPL/ml), anti-ß-2-glycoprotein antibodies (IGG: 25 UG), and lupus anticoagulant positive. The tests were repeated 12 weeks later and the results were similar confirming the diagnosis of APS. Based on the lab results, antithrombotic treatment was initiated based on enoxaparin 60 mg/day for seven days and acenocoumarol 4 mgs/day until a stable international normalized ratio of 3.5 was achieved. Neither steroids nor cyclophosphamide were indicated during this first episode.
After the first episode of DVT, the patient had four more relapses about a year or so apart, two on each leg, mainly because of lack of adherence to anticoagulant treatment. After the second relapse, the patient developed various sized ulcers in the distal segment of his legs. These resolved after rest, anticoagulant dose adjustment, and treatment with antibiotics because of a positive culture for coagulase positive Staphylococcus aureus.
In May 2012, five necrotic ulcers of different sizes reappeared in the distal segment of the patient's left leg. The largest was 102 cm 2 (Figure 1(a) ), which was biopsied, including its edges. The cutaneous histopathologycal study reported a non-inflammatory vascular thrombosis. Additionally, the patient complained of severe pain in both feet, and Raynaud's phenomenon (RP) in 5 toes; therefore, we added nifedipine (Adalat, Bayer Schering Pharma, Germany) at a dose of 10 mg orally twice daily to relieve vasospasms, as well as rivaroxaban (Xarelto, Bayer Schering Pharma, Germany) 10 mg/day, and tramadol 200 mg twice daily. However, there was no relief of symptoms after two weeks of treatment, so prednisone (1 mg/kg/day), intravenous cyclophosphamide 1 g/day monthly, and oral gabapentin 600 mg twice daily were prescribed. To treat positive anaerobic cultures, clindamycin 300 mg twice daily was administered, and fetid necrotic eschars that were covering the ulcers were debrided. Subcutaneous insulin glargine 12 units/day before a meal was given as a result of an unexpected rise in the patient's fasting serum glucose, which was over 200 mg/dL.
Case Evolution and Discussion
Though rare, skin ulceration and gangrene can occur in patients with APS who have an active vasculitis. These kinds of ulcers are considered intractable because healing is difficult to achieve in patients who are exposed to immunosupressants, resulting in an uncertain prognosis [7] .
Leg ulcers with a surface area larger than 100 cm 2 are common in patients with autoimmune diseases and are the most difficult to heal. The primary treatment most be continued, although the administration of immunosuppressive therapies like steroids, cyclophosphamide, cyclosporin, and azathioprine slows the deposition of granulation tissue, inhibits the immune response, and promotes the infection [10] .
The subsequent management of our patient consisted of wide surgical debridement and resection of the devitalized tissue (Figure 1(b) ), infection control with intravenous ertapenem (Invanz, Merck Sharp & Dohme) 1 g/day. For 2 weeks. Sildenafil citrate (Viagra, Pfizer, New York, NY) 50 mg/day was given because of a sudden violet coloring on the edge of the ulcer as shown in Figure 1 (c) that we thought was RP secondary to vasculitis based on previous studies. The RP was reversed with PDE-5 inhibitors until graft integration (Figures 1(g)-(i) ). The toes on both feet were discolored (images not shown).
When considering ischemic wounds, the literature indicates that the infection does not normally respond to systemic antibiotic therapy [11] . This patient also repeatedly applied peroxide solution to the wound. Nevertheless, hyperalgesia was an important limitation of this process. Pain due to wound healing causes patients to fear, distrust, and reject the process. For pain control, a tunneled peridural catheter was inserted to administer a combination of bupivacaine and morphine by infusion pump [12] . Prior to any wound manipulation, a lidocaine bolus was used. Multiple treatments have been proposed to accelerate the deposition of granulation tissue and decrease wound healing frequency [13] . Therefore, we employed fat dressings with sterile Vaseline and zinc oxide, which offers a moist environment and easier periodic replacement.
Adequate control of glucose was achieved through the insulin glargine, which improved good integration of the graft in order to obtain a complete cutaneous cover over all the lesions.
Recently, various possible sites of action of the therapeutic interventions used to treat lesions in patients with APS have been reported [14] . Not all of the interventions were successful, and others are not accessible to patients because of their costs or poor treatment adherence due adverse effects. We tried a new adjuvant therapeutic option that improves the vasospastic phenomenon, reduces pain symptoms associated with vasculitis, and favors ulcer cicatrization [15] . The doses of glargine and prednisone were also reduced.
Many animal experimental models in the literature have reported on the benefits of adjuvant use of PDE-5 inhibitors like sildenafil citrate [16] - [19] in different clinical entities similar to RP like scleroderma [15] , including the use of tadalafil in patients with RP secondary to mixed connective tissue disease-scleroderma and resistance to vasodilator therapy [20] . The potential mechanism of action involves NO donation mediated by endothelial NO synthase [14] .
Conclusion
This is the first report in the scientific literature demonstrating the additional benefit of the sildenafil citrate for the integration of grafts in a patient with APS and steroid-induced diabetes who had ulcers due to vasculitis that were resistant to usual vasodilator therapy.
